The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis

Autor: Roberta Ricciardi, Melania Guida, Marco Lucchi, Alfredo Mussi, Angela Lopomo, Michelangelo Maestri, Franca Melfi, Fabio Coppedè, Lucia Migliore, Anna De Rosa
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Male
Folate
Receptors
Nicotinic

Nicotinic
Thymidylate synthase
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Lymphoid hyperplasia
Genotype
Receptors
Promoter Regions
Genetic

biology
General Medicine
Single Nucleotide
Hyperplasia
Middle Aged
Ferredoxin-NADP Reductase
Enhancer Elements
Genetic

Myasthenia Gravis
Polymorphisms
Thymic hyperplasia
Thymoma
TYMS
Adult
Aged
Female
Genetic Predisposition to Disease
Humans
Methylenetetrahydrofolate Reductase (NADPH2)
Thymidylate Synthase
Thymus Hyperplasia
Polymorphism
Single Nucleotide

Genetics
medicine.symptom
medicine.medical_specialty
Enhancer Elements
Promoter Regions
03 medical and health sciences
Genetic
Internal medicine
medicine
Polymorphism
medicine.disease
MTRR
Myasthenia gravis
030104 developmental biology
Endocrinology
Methylenetetrahydrofolate reductase
Cancer research
biology.protein
Popis: Background Myasthenia Gravis (MG) is caused, in approximately 80% of the patients, by autoantibodies against the nicotinic acetylcholine receptor (AChR). The disease is often associated with pathological changes of the thymus: thymic epithelial tumours are present in about 10–20% of the patients, while up to 80% of the patients with early disease onset have thymic hyperplasia. Folate metabolism is required for the production of DNA precursors and for proper DNA methylation reactions, and impaired folate metabolism has been often associated with cellular growth and cancer. Methods We investigated if major polymorphisms of folate-related genes, namely MTHFR c.677C > T, MTR c.2756A > G, MTRR c.66A > G and TYMS TSER (a 28-bp tandem repeat in the 5′ promoter enhancer region of TYMS) increase the risk of pathological changes of the thymus in AChR + MG patients. A total of 526 AChR + MG patients, including 132 patients with normal (involuted) thymus, 146 patients with thymic hyperplasia, and 248 patients with a thymoma were included in the study. Allele and genotype comparisons were performed among the three study groups, after correcting for multiple testing. Results The frequency of the TYMS TSER 3R allele was significantly higher in MG patients with thymic hyperplasia (P = 0.004), and the TYMS TSER 3R3R genotype was significantly associated with increased risk of thymic hyperplasia [OR 2.71 (95% CI: 1.34–5.47)]. Conclusions The 3R allele in the thymidylate synthase promoter enhancer region results in increased protein production, required for the synthesis of DNA precursors. The present study suggests that the TYMS TSER 3R allele increases the risk of thymic lymphoid hyperplasia in AChR + MG patients.
Databáze: OpenAIRE